The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Company profile
Ticker
BMY
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1096271 BC ULC • 345 Park LLC • 9643435 Canada Inc. • Abraxis BioScience Australia Pty Ltd. • Abraxis BioScience International Holding Company, Inc. • Abraxis BioScience Puerto Rico, LLC • Abraxis BioScience, Inc. • Abraxis BioScience, LLC • AbVitro LLC • Acetylon Pharmaceuticals, Inc. ...
IRS number
220790350
BMY stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
9 May 24
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
25 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
8-K
Strengthening Neuroscience Portfolio
18 Mar 24
Transcripts
BMY
Earnings call transcript
2024 Q1
25 Apr 24
BMY
Earnings call transcript
2023 Q4
2 Feb 24
BMY
Earnings call transcript
2023 Q3
26 Oct 23
BMY
Earnings call transcript
2023 Q2
27 Jul 23
BMY
Earnings call transcript
2023 Q1
27 Apr 23
BMY
Earnings call transcript
2022 Q4
2 Feb 23
BMY
Earnings call transcript
2022 Q3
26 Oct 22
BMY
Earnings call transcript
2022 Q2
27 Jul 22
BMY
Earnings call transcript
2022 Q1
29 Apr 22
BMY
Earnings call transcript
2021 Q4
4 Feb 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.33 bn | 9.33 bn | 9.33 bn | 9.33 bn | 9.33 bn | 9.33 bn |
Cash burn (monthly) | 728.33 mm | (no burn) | 3.84 bn | 487.17 mm | (no burn) | (no burn) |
Cash used (since last report) | 1.20 bn | n/a | 6.34 bn | 804.26 mm | n/a | n/a |
Cash remaining | 8.13 bn | n/a | 3.00 bn | 8.53 bn | n/a | n/a |
Runway (months of cash) | 11.2 | n/a | 0.8 | 17.5 | n/a | n/a |
Institutional ownership, Q4 2023
53.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1986 |
Opened positions | 201 |
Closed positions | 553 |
Increased positions | 545 |
Reduced positions | 1042 |
13F shares | Current |
---|---|
Total value | 52.83 tn |
Total shares | 1.09 bn |
Total puts | 7.41 mm |
Total calls | 11.59 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 198.16 mm | $10.17 tn |
JPM JPMorgan Chase & Co. | 90.05 mm | $4.62 tn |
STT State Street | 89.45 mm | $4.59 tn |
Capital International Investors | 61.53 mm | $3.16 tn |
FMR | 42.61 mm | $2.19 tn |
MS Morgan Stanley | 29.38 mm | $1.51 tn |
NTRS Northern Trust | 24.01 mm | $1.23 tn |
Primecap Management | 23.53 mm | $1.21 tn |
LGEN Legal & General | 19.81 mm | $1.02 tn |
BK Bank Of New York Mellon | 17.02 mm | $873.41 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | Adam Lenkowsky | Market Share Units Common Stock, $0.10 par value | Other | Dispose J | No | No | 0 | 1,373 | 0.00 | 4,121 |
1 Apr 24 | Karin Shanahan | Common Stock, $0.10 par value | Payment of exercise | Dispose F | No | No | 52.99 | 1,196 | 63.38 k | 5,336 |
1 Apr 24 | Karin Shanahan | Common Stock, $0.10 par value | Option exercise | Acquire M | No | No | 0 | 3,306 | 0.00 | 6,532 |
1 Apr 24 | Karin Shanahan | RSU Common Stock, $0.10 par value | Option exercise | Dispose M | No | No | 0 | 3,306 | 0.00 | 6,613 |
31 Mar 24 | Yale Phyllis R | Deferred Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 54.23 | 645.399 | 35.00 k | 27,595.249 |
31 Mar 24 | Storch Gerald L | Deferred Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 54.23 | 691.499 | 37.50 k | 88,158.649 |
31 Mar 24 | Samuels Theodore R. II | Deferred Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 54.23 | 921.999 | 50.00 k | 47,858.919 |
News
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
17 May 24
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
16 May 24
Bristol Myers Squibb Presents New 4-Year Sotyktu Data Demonstrate Durable Response Rates And Consistent Safety In Moderate-To-Severe Plaque Psoriasis
16 May 24
10 Health Care Stocks With Whale Alerts In Today's Session
14 May 24
Bristol Myers Squibb Shares Update On Phase 3 CheckMate -73L Trial; Says Trial Did Not Meet Its Primary Endpoint Of Progression-Free Survival In Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer
10 May 24
Press releases
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
16 May 24
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
15 May 24
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
15 May 24
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
10 May 24
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb
30 Apr 24